Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
Ernexa Therapeutics has made significant progress in manufacturing and regulatory activities for its lead oncology candidate ERNA-101, an engineered allogeneic iMSC therapy targeting immunologically cold tumors. The company plans to submit an Investigational New Drug (IND) application in Q3 2026 with a first-in-human Phase 1 study expected in Q4 20…